A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety,
immunogenicity, and relative vaccine efficacy of mRNA-1283.222 administered as a booster
dose compared with mRNA-1273.222 in participants aged 12 years and older for the prevention
of COVID-19